The kidney in acromegaly: Renal structure and function in patients with acromegaly during active disease and 1 year after disease remission

European Journal of Endocrinology

Volumn 162, Issue 6, 2010, Pages 1035-1042

  Auriemma, Renata S ^a   Galdiero, Mariano ^a   De Martino, Maria C ^a   De Leo, Monica ^a   Grasso, Ludovica F S ^a   Vitale, Pasquale ^a   Cozzolino, Alessia ^a   Lombardi, Gaetano ^a   Colao, Annamaria ^a   Pivonello, Rosario ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BICARBONATE; CALCIUM; CITRIC ACID; CREATININE; GROWTH HORMONE; HYDROXYPROLINE; OXALIC ACID; PHOSPHORUS; POTASSIUM; SODIUM; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE; UREA; URIC ACID;

ACROMEGALY; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BODY SURFACE; CALCIUM URINE LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; COURSE EVALUATION; CREATININE CLEARANCE; DISEASE DURATION; ECHOGRAPHY; FEMALE; GROWTH HORMONE BLOOD LEVEL; HUMAN; HYDROXYPROLINE URINE LEVEL; KIDNEY FUNCTION; KIDNEY SIZE; KIDNEY STRUCTURE; MALE; MICROALBUMINURIA; NEPHROLITHIASIS; POTASSIUM EXCRETION; POTASSIUM URINE LEVEL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REMISSION; SEX DIFFERENCE; SODIUM EXCRETION; SODIUM URINE LEVEL; URIC ACID URINE LEVEL; URINALYSIS; URINE LEVEL;

ACROMEGALY; ADULT; AGED; CITRIC ACID; CREATININE; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; KIDNEY; MALE; MIDDLE AGED; REMISSION INDUCTION; SOMATOSTATIN;

EID: 77952685718     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-10-0007     Document Type: Article

References (44)

1. Cingel-Ristic V, Flyvbjerg A & Drop SL. The physiological and pathophysiological roles of the GH/IGF-I-axis in the kidney: lessons from experimental rodent models. Growth Hormone & IGF Research 2004 14 418-430. (Pubitemid 40298322)
2. Feld S & Hirschgerg R. Growth hormone, the insulin-like growth factor system, and the kidney. Journal of Clinical Endocrinology and Metabolism 1996 5 423-480. (Pubitemid 26346638)
3. Reddy GR, Pushpanathan MJ, Ransom RF, Holzman LB, Brosius FC III, Diakonova M, Mathieson P, Saleem MA, List EO, Kopchick JJ, Frank SJ & Menon RK. Identification of the glomerular podocyte as a target for growth hormone action. Endocrinology 2007 148 2045-2055. (Pubitemid 46997041)
4. Dimke H, Flyvbjerg A & Frische S. Acute and chronic effects of growth hormone on renal regulation of electrolyte and water homeostasis. Growth Hormone & IGF Research 2007 17 353-368. (Pubitemid 47336876)
5. Hirschberg R & Kopple JD. Effects of growth hormone and IGF-I on renal function. Kidney International 1989 27 S20-S26.
6. Baldelli R, De Marinis L, Bianchi A, Pivonello R, Gasco V, Auriemma RS, Pasimeni G, Cimino V, Appetecchia M, Maccario M, Lombardi G, Pontecorvi A, Colao A & Grottoli S. Microalbuminuria in insulin sensitivity in patients with growth hormone-secreting pituitary tumor. Journal of Clinical Endocrinology and Metabolism 2008 93 710-714. (Pubitemid 351398543)
7. Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, von Werder K & Melmed S. Criteria for cure of acromegaly: a consensus statement. Journal of Clinical Endocrinology and Metabolism 2000 85 526-529. (Pubitemid 32273628)
8. Lenfant C, Chobanian AV, Jones DW& Rocella EJ. Seventh Report of the Joint NationalCommittee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7): Resetting the hypertension sails. Hypertension 2003 41 1178-1179. (Pubitemid 36706061)
9. IDF clinical guidelines task force. Global Guideline for Type 2 Diabetes: recommendations for standard, comprehensive, and minimal care. Diabetic Medicine 2006 23 579-593.
10. Salcedo-Alejos M, Banda-Espinoza F, Rodriguez-Moràn M & Guerrero-Romero F. Irbesartan reduces creatinine clearance in type 1 diabetic children with renal hyperfunction: a randomized, double-blind, placebo-controlled trial. Nephrology, Dialysis, Transplantation 2005 20 2120-2125. (Pubitemid 41510086)
11. Segura J, Praga M, Campo C, Rodicio JL & Ruilope LM. Combination is better than monotherapy with ACE inhibitor or angiotensin receptor antagonist at recommended doses. Journal of Renin-Angiotensin-Aldosterone System 2003 4 43-47. (Pubitemid 36443386)
12. Bauer JH, Brooks CS & Burch RN. Clinical appraisal of creatinine clearance as a measurement of glomerular filtration rate. American Journal of Kidney Diseases 1982 2 337-346. (Pubitemid 13142496)
13. Delanaye P, Cavalier E, Mariat C, Maillard N, Dubois BE & Krzesinski JM. Detection and estimation of chronic kidney disease. Revue Médicale de Liége 2009 64 73-78.
14. Moller N, Vendelbo MH, Kampmann U, Christensen B, Madsen M, Norrelund H & Jorgensen JO. Growth hormone and protein metabolism. Clinical Nutrition 2009 28 597-603.
15. Swärd K, Valsson F, Sellgren J & Ricksten SE. Differential effects of human natriuretic peptide and furosemide on glomerular filtration rate and renal oxygen consumption in humans. Intensive Care Medicine 2005 31 79-85. (Pubitemid 40174285)
16. Middleton WD, Dodds WJ, Lawson TL & Foley WD. Renal calculi: sensitivity for detection with US. Radiology 1988 167 239-244.
17. Hammerman MR & Miller SB. Renal cellular biology of growth hormone and insulin-like growth factor I. Pediatric Nephrology 1991 5 505-508.
18. Kawaguchi H, Itoh K, Mori H, Hayashi Y & Makino S. Renal pathology in rats bearing tumor-secreting growth hormone. Pediatric Nephrology 1991 5 533-538.
19. Blazer-Yost BL, Watanabe M, Haverty TP & Ziyadeh FN. Role of insulin and IGF-I receptors in proliferation of cultured renal proximal tubule cells. Biochimica et Biophysica Acta 1992 1133 329-335.
20. Hoogenberg K, Sluiter WJ & Dullaart RP. Effect of growth hormone and insuline-like growth factor I on urinary albumin excretion: studies in acromegaly and growth hormone deficiency. Acta Endocrinologica 1993 129 151-157. (Pubitemid 23254832)
21. Manelli F, Bossoni S, Burattin A, Doga M, Solerte SB, Romanelli G & Giustina A. Exercise-induced microalbuminuria in patients with active acromegaly: acute effects of slow-release lanreotide, a long-acting somatostatin analog. Metabolism 2000 49 634-639. (Pubitemid 30305263)
22. Ng LL & Evans DJ. Leucocyte sodium transport in acromegaly. Clinical Endocrinology 1987 26 471-480.
23. Shimomura Y, Lee M, Oku J, Bray GA & Glick Z. Sodium potassium dependent ATPase in hypophysectomized rats: response to growth hormone, triiodothyronine, and cortisone. Metabolism 1982 31 213-216. (Pubitemid 12176907)
24. Dimke H, Flyvbjerg A, Bourgeois S, Thomsen K, Frokiaer J, Houillier P, Nielsen S & Frische S. Acute growth hormone administration induces antidiuretic and antinatriuretic effects and increases phosphorylation of NKCC2. American Journal of Physiology. Renal Physiology 2007 292 723-735.
25. Kamenicky P, Viengchareun S, Blanchard A, Meduri G, Zizzari P, Imbert-Teboul M, Doucet A, Chanson P & Lombès M. Epithelial sodium channel is a key mediator of growth hormone-induced sodium retention in acromegaly. Endocrinology 2008 149 3294-3305.
26. Pines A & Olchovsky D. Urolithiasis in acromegaly. Urology 1985 26 240-242.
27. Hielberg IP, Czepielewski MA, Ajzen H, Ramos OL & Schor N. Metabolic factors for urolithiasis in acromegalic patients. Brazilian Journal of Medical and Biological Research 1991 24 687-696.
28. Park S & Pearle MS. Pathophysiology and management of calcium stones. Urologic Clinics of North America 2007 34 323-334.
29. Parkinson C, Kassem M, Heickendorff L, Flyvbjerg A & Trainer PJ. Pegvisomant-induced serum insulin-like growth factor-I normalization in patients with acromegaly returns elevated markers of bone turnover to normal. Journal of Clinical Endocrinology and Metabolism 2003 88 5650-5655. (Pubitemid 38033029)
30. Pak CY, Adams-Huet B & Pinodexter JR. Rapid communication: relative effect of urinary calcium and oxalate on saturation of calcium oxalate. Kidney International 2004 66 2032-2037.
31. Caudarella R, Vescini F, Buffa A & Stefoni S. Citrate and mineral metabolism: kidney stones and bone disease. Frontiers in Bioscience 2003 8 1084-1106.
32. Lepszy H, Irmscher K, Wiegelmann W, Solbach HG & Krüskemper HL. Urinary excretion of hydroxyproline in acromegaly. Deutsche Medizinische Wochenschrift 1976 101 857-861.
33. Özkurt H. Frequency of microalbuminuria and its relationship with other atherosclerotic risk factors in nondiabetic hypertensive patients. Anadolu Kardiyoloji Dergisi 2007 7 224-226.
34. Klausen KP, Parving HH, Scharling H & Jensen JS. The association between metabolic syndrome, microalbuminuria and impaired renal function in the general population: impact on cardiovascular disease and mortality. Journal of Internal Medicine 2007 262 470-478. (Pubitemid 47404367)
35. Mangrum A & Bakris GL. Predictors of renal and cardiovascular mortality in patients with non-insulin-dependent diabetes: a brief overview of microalbuminuria and insulin resistance. Journal of Diabetes and its Complications 1997 11 352-357. (Pubitemid 27488777)
36. Reaven GM, Lithell H & Landsberg L. Hypertension and associated metabolic abnormalities - the role of insulin resistance and the sympathoadrenal system. New England Journal of Medicine 1996 334 374-381. (Pubitemid 26049592)
37. El-Atat FA, Stas SN, McFarlane SI & Sowers JR. The relationship between hyperinsulinemia, hypertension and progressive renal disease. Journal of the American Society of Nephrology 2004 15 2816-2827. (Pubitemid 41103390)
38. Yuyun MF, Khaw KT, Luben R, Welch A, Bingham S, Day NE & Wareham NJ. A prospective study of microalbuminuria and incident coronary heart disease and its prognostic significance in a British population: the EPIC-Norfolk study. American Journal of Epidemiology 2004 159 284-293. (Pubitemid 38141658)
39. Borch-Johnsen K, Feldt-Rasmussen B, Strandgaard S, Schroll M & Jensen JS. Urinary albumin excretion. An independent predictor of ischemic heart disease. Arteriosclerosis, Thrombosis, and Vascular Biology 1999 19 1992-1997. (Pubitemid 29379934)
40. Romundstad S, Holmen J, Kvenild K, Hallan H & Ellekjaer H. Microalbuminuria and all-cause mortality in 2,089 apparently healthy individuals: a 4.4-year follow-up study. The Nord- Trøndelag Health Study (HUNT), Norway. American Journal of Kidney Diseases 2003 42 466-473. (Pubitemid 37048122)
41. Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, Gans RO, Janssen WM, Grobbee DE, de Jong PE & Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002 106 1777-1782.
42. Arnlöv J, Evans JC, Meigs JB, Wang TJ, Fox CS, Levy D, Benjamin EJ, D'Agostino RB, Vasan RS & Framingham Heart Study, National Heart, Lung and Blood Institute, Bethesda, MD, USA. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation 2005 112 969-975.
43. Schmieder RE, Schrader J, ZidekW, Tibbe U, Paar WD, Bramlage P, Pittrow D & Bönm M. Low-grade albuminuria and cardiovascular risk.What is the evidence? Clinical Research in Cardiology 2007 96 247-257.
44. Colao A, Ferone D, Marzullo P & Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocrine Reviews 2004 25 102-152. (Pubitemid 38269977)